Skip to main content
Retour
Watch Compare

Medicus Pharma Ltd.

Qualité des données : 83%
Également cotée sous MDCXW Nasdaq
MDCX
Nasdaq Manufacturing Chemicals
0,41 €
▼ 0,03 € (-6,33%)
Cap. Boursière: 17,61 M
Prix
0,45 €
Cap. Boursière
17,61 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -22,78 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-4043,60%
En dessous de la moyenne du secteur (-53,41%)
ROIC-2003,07%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio0,92
Interest Coverage-174,08

Valorisation

PE (TTM)
-0,37
Au-dessus de la moyenne du secteur (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -0,4 -1,5
P/B — 1,6
ROE % -4043,6 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -47,28 M
ROE -4043,60% ROA -431,55%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -22,78 M
ROIC -2003,07% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,92
Interest Coverage -174,08 Asset Turnover N/A
Working Capital -876 489 Tangible Book Value -910 126
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,37 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -129,36%
Market Cap 17,61 M Enterprise Value 8,94 M
Per Share
EPS (Diluted TTM) -2,74 Revenue / Share N/A
FCF / Share -0,58 OCF / Share -0,58
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 48,17%
SBC-Adj. FCF -24,29 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue — —
Net Income -47,28 M -11,16 M
EPS (Diluted) -2,74 -1,16
Gross Profit — —
Operating Income -34,36 M -11,18 M
EBITDA — —
R&D Expenses 7,72 M 3,53 M
SG&A Expenses — —
D&A — —
Interest Expense -197 382,0 —
Income Tax 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 10,06 M 5,65 M
Total Liabilities 10,02 M 2,51 M
Shareholders' Equity -67 554,0 3,13 M
Total Debt — —
Cash & Equivalents 8,71 M 4,16 M
Current Assets 9,89 M 5,38 M
Current Liabilities 9,94 M 2,31 M